Cameron Health’s Subcutaneous ICD Gains FDA Panel Endorsement
This article was originally published in The Gray Sheet
Executive Summary
Following the panel vote April 26, Cameron CEO Kevin Hykes told “The Gray Sheet” that the company expects to receive PMA approval in the first half of 2013, as previously anticipated.
You may also be interested in...
Subcutaneous ICD Matches Standard ICD In Controlled Trial
Short-term results in a study of Boston Scientific's S-ICD device show promise, but also point to room for improvement.
New Products In Brief
Recent new product launches and approvals include Boston Scientific’s novel S-ICD subcutaneous implantable cardioverter defibrillator, Globus Medical’s Secure-C artificial cervical disc and ConforMIS’ next-generation iTotal G2 total knee replacement.
Boston Scientific Buys Cameron Health For First Subcutaneous ICD
Deal includes $150 million up front, but is worth up to $1.35 billion with potential milestone payments.